BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29 ...

Financially, Verve has a market cap of $475mn, cash balance of $540mn, and a cash runway of 7-8 quarters. Find out my ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 25.48% ...

EXCLUSIVE: Academy Award-winning NYC studio Believe Entertainment Group has signed with Verve for representation. The news ...

Verve, the literary and talent agency, is adding to its leadership ranks. The Los Angeles-based representation firm has hired executive Jennifer Jones as its general counsel/head of business ...

Bill Weinstein has sued Verve talent agency stemming from his exit after a little more than a year as chief executive, accusing the firm's leadership of conspiring to oust him in a move to sell ...

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.